Current Report Filing (8-k)
March 12 2020 - 4:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): March 12, 2020
___________________________
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified
in its charter)
___________________________
Nevada
|
001-39126
|
82-2318545
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
2100 West Loop South, Suite 900
Houston,Texas 77027
(Address of principal executive
offices) (Zip Code)
Registrant’s telephone number,
including area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
___________________________
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbols(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
CNSP
|
The NASDAQ Stock Market LLC
|
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 12, 2020, CNS Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing business highlights and financial results for the three months
ended December 31, 2019 and fiscal year 2019.
The information contained in Item 2.01 of
this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for
the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein
as being incorporated by reference.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
Signature
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
CNS Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Chris Downs
|
|
|
|
Chris Downs
|
|
|
|
Chief Financial Officer
|
|
Dated: March 12, 2020
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Jul 2023 to Jul 2024